Evidence map›Paper›PMID 42591230›Full record

ArticleFrontiers in immunology2026

Microfluidic dissociation of spleen to recover immune cells for biotechnology and single cell analysis.

Jeremy A Lombardo, David Zalazar, Marzieh Aliaghaei, Jered B Haun

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jeremy A Lombardo *Department of Biomedical Engineering, University of California, Irvine, Irvine, CA, United States.
David Zalazar *Department of Biomedical Engineering, University of California, Irvine, Irvine, CA, United States.
Marzieh AliaghaeiDepartment of Chemical and Biomolecular Engineering, University of California, Irvine, Irvine, CA, United States.
Jered B HaunDepartment of Biomedical Engineering, University of California, Irvine, Irvine, CA, United States.

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Microfluidic tumor tissue processing platform for single cell diagnosticsR33CA251006 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI HAUN, JERED BRACKSTON · 2021 to 2023
$1.1M
Microfluidic system for complete and automated dissociation of tumor tissue into single cellsR43CA272118 · NCI · KINO DISCOVERY, INC. · PI DUHAY, FRANCIS · 2022 to 2022
$311k
NCI NIH HHS P30 CA062203NCI NIH HHS R33 CA251006NCI NIH HHS R43 CA272118
6 · The paper itself

Abstract

Introduction: Splenocytes are important for various applications in medicine and biotechnology, but isolation methods are often limited by low yield, poor viability, bias towards certain cell subtypes, and degradation of surface marker expression. Here, we employ a microfluidic device to dissociate spleen tissue and isolate single splenocytes using non-enzymatic, enzymatic, and combined approaches. Methods: Spleen samples were minced and digested on-chip using enzyme-free buffer to assess short-term release of predominantly non-adherent CD45+ leukocyte populations. We then evaluated isolation of dendritic cells and macrophages by comparing non-enzymatic and enzymatic digestion protocols over time. A combined protocol, consisting of a buffer washout followed by collagenase digestion, was then used to balance enzyme exposure and maximize recovery. Results: Microfluidic digestion yielded greater cell recovery and viability across non-adherent splenocytes (B cells and T cell subpopulations) and adherent splenocytes (dendritic cells, macrophages, and neutrophils) within the CD45+ leukocyte population, compared to conventional strainer grinding and collagenase digestion controls. Functional validation was performed for B cells, which were isolated using the final protocol and cultured for six days, demonstrating comparable proliferation, viability, and antibody production levels relative to controls. Discussion: Future studies will evaluate additional splenocyte subpopulations using functional assays and downstream applications in medicine and biotechnology.

Indexed as

Cell SeparationMicrofluidicsSingle-Cell AnalysisSpleenAnimalsDendritic CellsFemaleLab-On-A-Chip DevicesLeukocyte Common AntigensLeukocytesMacrophagesMiceLeukocyte Common Antigensdissociationmicrofluidicsingle cellspleensplenocyte

Identifiers

PMID42591230
PMCPMC13461508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.